Lecture 11

Hypothesis Testing: Comparing Parameters (Means, Proportions, Incidence Rates) Between More Than 2 Populations With One Test

Section A: (Hypothesis Testing) Comparing Means Between More Than Two Populations: Analysis of Variance (ANOVA)

Learning Objectives

- In this lecture section you will learn to interpret a p-value from a hypothesis test for (any) mean differences between more than two populations
- The method for getting the p-value is called the Analysis of Variance (frequently called ANOVA)

Example 1

- Researchers were interested in the relationship between smoking and mid-expiratory flow (FEF), a measure of pulmonary health. The researchers recruited study subjects and classified them into one of six smoking categories¹
 - Nonsmokers (NS)
 - Passive smokers (PS)
 - Non-inhaling smokers (NI)
 - Light smokers (LS)
 - Moderate smokers (MS)
 - Heavy smokers (HS)

¹ White, J.R., Froeb, H.F. Small-Airways Dysfunction in Non-Smokers Chronically Exposed to Tobacco Smoke, New England Journal of Medicine 302: 13 (1980)

Example 1

- To start, the researchers were interested in whether there were any statistically significant differences in pulmonary outcomes (FEV1, FEF, etc..) between the six underlying populations
- One strategy would be to perform lots of two-sample t-tests (for each possible two-group comparison)
- In this example, there would be 15 such comparisons!
 NS to PS, NS to NI, and so on . . .

Example 1

- Analysis of Variance (One-Way ANOVA) is an extension of the twosample (unpaired) t-test to compare means between more than two populations with one test
- General idea behind ANOVA, comparing means for k-groups (k > 2):

 $H_0: \mu_1 = \mu_2 = \dots \mu_k$

H_A: At least one mean different

- Smoking and FEF
 - From a pool of over 5,200 potential participants, a random sample of 200 men and 200 women was drawn from each smoking group (except for the non-inhalers, where 50 men and 50 women were selected)
 - FEF measurements were taken on each of the subjects

Table	1													
	ol. 302 No. 13				S DYSFUN	OTHOR: IN	Nove	OVERS	w1077	AND ED	DEB.		721	
,	ot. 302 No. 13	3047	L	AIRWAI	DISPUN	LIION IN	NONSSI	OKERS -	WHILE	AND PR	JEB		/21	
	Table 1. Vital	Capacit	ies	and Expir	atory Flow	Rate (Med	an ±S.D.	in Male a	nd Femi	ale Smoke	rs and t	Vonsmoke	ers.	
	Geoup	No. or Sussects	Sex	Ace	Наюнт	P	rc	FE	v,	FEF 2	-75%	FEF 25	45%	
				**	œ	ltiers	% predicted	liters	% predicted	liter/sec	% predicted	lizer/sec	% predicted	
1	Nonsmokers, no smoky environment	200 200	F M		162.05±6.58 176.3±7.77		102 102	2.63±0.63 3.72±0.65	104 103	3.17±0.74 3.78±0.79	108 104	1.03±0.38 1.22±0.35	112 120	
2	- Nonsmokers, smoky environ- ment > 20 yr	200 200	F M		161.8±6.68 176.02±6.55		98 99	2.47±0.63 3.54±0.61	99 98	2.72±0.71* 3.30±0.77*	93 91	0.78±0.36* 0.97±0.34*	85 95	
3	-Smokers not inhaling cigarettes, pipe, or cigars	50 50		46.93±7.10 47.6±7.38	159±7.09 174.5±7.42	3.19±0.52 4.63±0.86	97 96	2.49±0.74 3.56±0.76	99 99	2.71±0.87* 3.32±0.86*	92 92	0.78±0.43° 0.89±0.47	85 87	
	>20 yr — Smokers inhaling	200			159.77±7.44		96	2.40±0.62	98	2.63±0.73*	89	0.76±0.31		
	1+10 cigarettes per day > 20 yr	200	М		175.9±7.44			3.49±0.62*	97	3.23±0.78*	89	0.79±0.36		
5	— Smokers inhaling 11-39 cigarettes per day > 20 yr	200 200	M		176.02±7.67		84	2.13±0.62* 3.08±0.61*	85 86	2.29±0.70* 2.73±0.81*	78 76	0.63±0.31 0.69±0.29	68	
•	— Smokers inhaling >40 cigarettes per day >20 yr	200 200	F M	45.98±6.73 47.8±7.44	159.26±7.29 176.53±7.9	2.55±0.38* 3.92±0.73*	78 82	2.01±0.64* 2.77±0.60*	80 77	2.12±0.72* 2.59±0.82*	72 72	0.57±0.33 0.61±0.31		
,	rediction for age: 46.8 yr, height 160.53 cm †	1050			160.3±6.99	3.28	-	2.52	-	2.94	-	0.92	-	
P	rediction for age: 48.3 yr, beight	1050	М	48.35±7.50	175.77±7.54	4.81	-	3.60	-	3.62	-	1.02	-	

Example 1

■ Data Summary, Males (FEF 25- 75%)

Group	Mean FEF	SD FEF		
	(L/s)	(L/s)	n	
NS	3.78	0.79	200	
PS	3.30	0.77	200	
NI	3.32	0.86	50	
LS	3.23	0.78	200	
MS	2.73	0.81	200	
HS	2.59	0.82	200	

Example 1

ANOVA comparing FEF values for males by smoking group

H_o: $\mu_{NS}=\mu_{PS}=\mu_{NI}=\mu_{LS}=\mu_{MS}=\mu_{HS}$ H_A: At least two groups have different means

- The p-value from ANOVA is very small: p < 0.01
 - Conclusion?

10

Example 1


 Overall summary of pulmonary comparisons, from abstract (based on follow-up two sample comparisons)

(P<0.005). When we looked at the extent to which smoke exposure is related to graded abnormality, we found that nonsmokers in smoke-free working environments have the highest scores on the spirometric tests; passive smokers, smokers who do not inhale, and light smokers score similarly and significantly lower; and heavy smokers score the lowest (P<0.005). We conclude that chronic exposure to tobacco smoke in the work environment is deleterious to the nonsmoker and significantly reduces small-airways function. (N Engl J Med. 1980; 302: 720-3.)

Example 2

- FEV1 and three medical centers ²
 - Data was collected on 60 patients with coronary artery disease at 3 difference medical centers (Johns Hopkins, Ranchos Los Amigos Medical Center, St. Louis University School of Medicine)
 - Purpose of study to investigate effects of carbon monoxide exposure on these patients
 - Prior to analyzing CO effects data, researchers wished to compared the respiratory health of these patients across the three medical centers

² Pagano M, Gauvreau K. Principles of Biostatistics. Second Edition. Duxbury Press (2000).



Boxplots ANOVA ■ Conclusions?

Example 2

- ANOVA approach, conceptually
 - Assume the null hypothesis is true
 - Compute a measure of discrepancy between what was observed in the sample compared to what is expected under the null (in ANOVA this is called a "F-statistic"
 - Compared this measure of discrepancy (F-statistic) to the distribution of such measures because of random sampling variability, when the null is true
 - Convert to a p-value

Example 2

• For this example, the F-statistic is 3.12. To get a p-value, this observed value is compared to a F-distribution with 2 numerator, and 57 denominator degrees of freedom

Example 2

• For this example, the F-statistic is 3.12. To get a p-value, this observed value is compared to a F-distribution with 2 numerator, and 57 denominator degrees of freedom

Example 3: Academic Physician Salaries³


■ From abstract


Results The mean salary within our cohort was \$167,669 (95%, CI, \$158,417-\$176,922) for women and \$200,433 (95%, CI, \$194,249-\$206,617) for men. Made gender was associated with higher salary (+\$13,899,F=0,01) even after adjustment in the final model for specialty, academic rank, leadership positions, publications, and research time, Peters-Belson analysis (use of coefficients derived from regression model for men applied to women) indicated that the expected mean salary for women, if be \$12,194 higher than observed.

Conclusion: Gender differences in salary exist in this select, homogeneous cohort of mid-career academic physicians, even after adjustment for differences in specialty, institutional characteristics, academic productivity, academic rank, work hours, and other factors.

AMA. 2012:307(22):2410-2417

³ Jagsi R, et al. Gender Differences in the Salaries of Physician Researchers. *Journal of the American Medical Association* (2012); 307(22); 2410-2417.





Summary

Section B: (Hypothesis Testing) Comparing Proportions Between More Than Two Populations: Chi-Square Tests

Learning Objectives

- In this lecture set you will learn to interpret a p-value for a hypothesis test comparing proportions between more than two populations
- The method for getting the p-value is an extension of the chi square test shown in lecture 10, and is also called a chi square test

Example 1

■ Health care indicators by immigrant status¹

Cipicatives. We examined the health datus and patterns of health care use of children in US Immigrant femilies.

All children Chair for the 1959 Notional Survey of Americas Families were used to create 3 subgroups of Immigrant children. US-born children with noncilizen parents, foreign home children with noncilizen parents. Chi-square and logistic represents entering the control of the control

¹ Huang, Z., et al. Health Status and Health Service Access and Use Among Children in U.S. Immigrant Families, *American Journal of Public Health* 96: 4 (2006)

23

■ Example: health care indicators by immigrant status¹

	US Born	, % (SE)	Foreign Born, % (SE)		
	Ottizon Perents	Noncitizon Percets	Gitizon (Naturelized)	Noncitizen	
Heelth and well being					
Fair/poor current health status	3.91(0.22)	13.52 (1.85)	4.05 (2.65)	12.22 (1.95)	
Negative behavior at ages 6-11 y	6.46 (0.56)	6.91 (2.00)	2.74 (1.76)	2.19 (1.05)	
Negative behavior at ages 12-17 y	7.50 (0.42)	3.58 (1.94)	1.49 (0.91)	8.46 (2.67)	
No implement in activities at ages 6-17 y	16.75 (3.53)	42.64 (3.29)	15.21 (3.67)	29.12 (2.50)	
Health insurance coverage and health care use and access					
Eack of medical insurance at any time in past 12 mo	15.34 (3.55)	34.37 (2.62)	12.86 (3.68)	52.3 (2.77)	
No usual source of care other than ER	5.78 (0.27)	18.21(1.93)	12.19 (4.18)	27.93 (2.63)	
At least one doctor visit in past year	77.03 (0.54)	65.43 (2.28)	77.04 (5.38)	51.75 (2.48)	
ER visit in post year	25.43 (0.47)	23.47 (1.96)	11.50 (3.62)	12.45 (1.72)	
At least one visit to duriful in past year (>3 y old)	80.47 (0.44)	62.73 (2.81)	84.65 (3.42)	55.50 (2.81)	
Wait to montel health-specialist in past year (2: 3y old)	7.17 (0.32)	2.83 (0.80)	5.55 (1.86)	1.77 (0.46)	
Subset of items tergeted specifically to families with					
incomes at or below 200% of FPI.					
Lack of medical insurance at any time in past 12 mo	26.68 (1.12)	38.76 (3.20)	37.19 (10.58)	68.58 (3.58)	
Current Medicaid/SCHP/state coverage	40.66 (0.95)	48.83 (3.30)	18.28 (5.48)	19.57 (2.50)	
Aware of separate SQRP program	50.25 (1.20)	48.51 (3.14)	46.6 (11.74)	39.71 (4.16)	
Aware of Medicaid program	89.85 (0.70)	99.83 (1.27)	89.95 (4.26)	50.79 (3.10)	

¹ Huang, Z., et al. Health Status and Health Service Access and Use Among Children in U.S. Immigrant Families, *American Journal of Public Health* 96: 4 (2006)

■ Zoom in | TABLE 2—Health Status, Health Care Access, and Health Care Use, by Immigrant Status: | National Survey of America's Families, 1999 | | US Born. % (SF) | | Critizen | | Noncitizen | | Noncitizen

Example 1

■ Chi Square Approach

27

TABLE 2—Health Status, Health Care Acc		th Care Use,	by Immigrant	Status:
National Survey of America's Families, 19		1, % (SE)	Foreign Bo	m, % (SE)
	Citizen Parents	Noncitizen Parents	Citizen (Naturalized)	Noncitizen
Lack of medical insurance at any time in past 12 mo	15.34 (0.55)	34.37 (2.62)	12.86 (3.68)	52.3 (2.77)
No usual source of care other than ER	5.78 (0.27)	18.21(1.93)	12.19 (4.18)	27.93 (2.63)
At least one doctor visit in past year	77.03 (0.54)	65.43 (2.28)	77.04 (5.38)	51.75 (2.48)
ER visit in past year	25.43 (0.47)	23.47 (1.96)	11.59 (3.62)	12.45 (1.72)
At least one visit to dentist in past year (≥3 y old)	80.47 (0.44)	62.73 (2.81)	84.65 (3.42)	55.59 (2.81)
Acteast one visit to definise in past year (≥ 5 y old)				

Example 2

Out of pocket spending, medication adherence: dialysis patients, 12 countries²

ABSTRACT: Few studies have examined drug costs and adherence in similar patient cohorts across countries. Using representative samples of hemodialysis patients from twelve countries, we examined out-of-pocker medication spending and cost-leaded nonadherence. Mean monthly spending ranged from \$81 in the United Kingdom to \$11.41 in the United States. The proportion of patients reporting nonadherence because of cost ranged from \$3 percent in Japan to 29 percent in the United States. Out-of-pooket spending was related to national pharmacountried financing policies and predicted national nonadherence rates. However, inconsistencies in the relationship between patient costs and nonadherence suggested that other social or policy factors also matter. [Health Affairs 27, no. 1 (2008): 89-102; 10.1377/hithaff 27.1.89]

 2 Hirth R, et al. Out-Of-Pocket Spending And Medication Adherence Among Dialysis Patients In Twelve Countries. Health Affairs (2008). 27 (1).

Example 2

• Characteristics of dialysis patients, 12 countries (six shown)

■ Percentage of minorities, compared across the 12 countries (only 6 countries shown)

EXHIBIT 1 Descriptive Measures Of The Prevalent Cross-Sectional Patient Sample, Dialysis Patients In Twelve Countries, 2002–2004

	A/NZ (n = 561)	BEL (n = 468)	CAN (n= 503	FRA (n = 481)	GER (n = 524)	ITA (n = 540)
Mean age (rears) Minority ^a	59.9 (14.7) 21.5%	66.2 (13.4) 5.3%	62.1 (14.7) 18.7%	64.1 (14.5) 7.1%	61.7 (14.1) 0.4%	64 (13.7) 0.4%
Income (\$US)						
<\$20,000	85.0%	73.4%	71.8%	67.0%	59.7%	78.3%
\$20,000-\$39,000	9.1	17.5	20.8	21.8	27.1	17.4
≥\$40,000	5.9	9.1	7.4	11.2	13.1	4.2
Insurance type						
National only	69.8%	74.1%	79.6%	45.5%	95.4%	99.6%
Private only	5.4	0.4	0.2	0.2	2.9	0.0
Mean number of						
comorbid conditions ^b	3.7(2)	3.9 (2.1)	4.1 (2.1)	3.1(1.9)	3.4 (2.1)	2.7 (1.9)
Mean number of			()	()	()	()
prescribed medications	8.7 (3.6)	9.9 (4.1)	12.6 (4.8)	7.7 (3.5)	9.7 (3.5)	6.4 (3.6)

Example 2

■ Percentage of minorities, compared across the 12 countries (only 6 countries shown)

EXHIBIT 1
Descriptive Measures Of The Prevalent Cross-Sectional Patient Sample, Dialysis Patients In Twelve Countries, 2002–2004

	A/NZ (n = 561)	BEL (n = 468)	CAN (n= 503	FRA (n = 481)	GER (n = 524)	ITA (n = 540)
Mean age (rears) Minority ^a	59.9 (14.7) 21.5%	66.2 (13.4) 5.3%	62.1 (14.7) 18.7%	64.1 (14.5) 7.1%	61.7 (14.1) 0.4%	64 (13.7) 0.4%
Income (\$US)						
<\$20,000	85.0%	73.4%	71.8%	67.0%	59.7%	78.3%
\$20,000-\$39,000	9.1	17.5	20.8	21.8	27.1	17.4
≥\$40,000	5.9	9.1	7.4	11.2	13.1	4.2
Insurance type						
National only	69.8%	74.1%	79.6%	45.5%	95.4%	99.6%
Private only	5.4	0.4	0.2	0.2	2.9	0.0
Mean number of						
comorbid conditions ^b	3.7(2)	3.9 (2.1)	4.1 (2.1)	3.1(1.9)	3.4 (2.1)	2.7 (1.9)
Mean number of	(-)		()	()	3(6.3)	
prescribed medications	8.7 (3.6)	9.9 (4.1)	12.6 (4.8)	7.7 (3.5)	9.7 (3.5)	6.4 (3.6)

Example 2

Distribution of income categories

EXHIBIT 1 Descriptive Measures Of The Prevalent Cross-Sectional Patient Sample, Dialysis Patients In Twelve Countries, 2002–2004

	A/NZ (n = 561)	BEL (n = 468)	CAN (n= 503	FRA (n = 481)	GER (n = 524)	ITA (n = 540)
Mean age (rears) Minority ^a	59.9 (14.7) 21.5%	66.2 (13.4) 5.3%	62.1 (14.7) 18.7%	64.1 (14.5) 7.1%	61.7 (14.1) 0.4%	64 (13.7) 0.4%
Income (\$US)						
<\$20,000	85.0%	73.4%	71.8%	67.0%	59.7%	78.3%
\$20,000-\$39,000	9.1	17.5	20.8	21.8	27.1	17.4
≥\$40,000	5.9	9.1	7.4	11.2	13.1	4.2
Insurance type						
National only	69.8%	74.2%	79.6%	45.5%	95.4%	99.6%
Private only	5.4	0.4	0.2	0.2	2.9	0.0
Mean number of						
comorbid conditions ^b	3.7(2)	3.9 (2.1)	4.1 (2.1)	3.1(1.9)	3.4 (2.1)	2.7 (1.9)
Mean number of						
presoribed medications	8.7 (3.6)	9.9 (4.1)	12.6 (4.8)	7.7 (3.5)	9.7 (3.5)	6.4 (3.6)

Example 2

Distribution of income categories

Example 2

■ ANOVA as well (previously lecture section infiltration!)

EXHIBIT 1 Descriptive Measures Of The Prevalent Cross-Sectional Patient Sample, Dialysis Patients In Twelve Countries, 2002–2004

	A/NZ (n = 561)	BEL (n = 468)	CAN (n= 503	FRA (n = 481)	GER (n = 524)	ITA (n= 540)
Mean age (rears) Minority ^a	59.9 (14.7) 21.5%	66.2 (13.4) 5.3%	62.1 (14.7) 18.7%	64.1 (14.5) 7.1%	61.7 (14.1) 0.4%	64 (13.7) 0.4%
Income (\$US)						
<\$20,000	85.09	73.4%	71.8%	67.0%	59.7%	78.3%
\$20,000-\$39,000	9.1	17.5	20.8	21.8	27.1	17.4
≥\$40,000	5.9	9.1	7.4	11.2	13.1	4.2
Insurance type						
National only	69.8%	74.1%	79.6%	45.5%	95.4%	99.6%
Private only	5.4	0.4	0.2	0.2	2.9	0.0
Mean number of						
comorbid conditions ^b	3.7(2)	3.9 (2.1)	4.1 (2.1)	3.1(1.9)	3.4 (2.1)	2.7 (1.9)
Mean number of						
prescribed medications	8.7 (3.6)	9.9 (4.1)	12.6 (4.8)	7.7 (3.5)	9.7 (3.5)	6.4 (3.6)

Example 3: Academic Physician Salaries³


■ From abstract


Results The mean salary within our cohort was \$167 669 (95% CI, \$158 417-\$176 922) for women and \$200433 (95% CI, \$194 249-\$206 617) for men. Male gender was associated with higher salary (+\$13 399; P=.001) even after adjustment in the final model for specially, academic rank, leadership positions, publications, and research time. Peters-Belson analysis (use of coefficients derived from regression model for men applied to women) indicated that the expected mean salary for women, if they retained their other measured characteristics but their gender was male, would be \$12 194 higher than observed.

Conclusion. Gender differences in salary exist in this select, homogeneous cohort of mid-career academic physicians, even after adjustment for differences in specialty. Institutional characteristics, academic productivity, academic rank, work hours, and other factors.

ractors. IAMA: 2012:307(22):2410-2417

³ Jagsi R, et al. Gender Differences in the Salaries of Physician Researchers. *Journal of the American Medical Association* (2012); 307(22); 2410-2417.





Summary 40

Section C: (Hypothesis Testing) Comparing Survival Curves Between More Than Two Populations: Log-rank Tests Learning Objectives


- In this lecture set you will learn interpret a p-value for a hypothesis test comparing survival curves (and hence incidence rates) between more than two populations
- The method for getting the p-value is an extension of the log rank test shown in lecture 10, and is also called a log rank test

■ Maternal Vitamin Supplementation and Infant Mortality

$$\mathit{IR} \ \hat{R}_{\mathit{vitd}} \ = \frac{\mathit{I} \hat{R}_{\mathit{vitd}}}{\mathit{I} \hat{R}_{\mathit{planebo}}} = \frac{0.00041 \quad \mathsf{deaths/day}}{0.00039 \quad \mathsf{deaths/day}} \approx 1.05$$


$$IR \ \hat{R}_{BC} = \frac{I\hat{R}_{BC}}{I\hat{R}_{placebo}} = \frac{0.00039}{0.00039} \frac{\text{deaths/day}}{\text{deaths/day}} \approx 1.00$$

1 Katz J, West K et al. Maternal low-dose vitamin A or 8-carotene supplementation has no effect on fetal loss and early infant mortality: a randomized cluster trial in Nepal. American Journal of Clinical Nutrition (2000) Vol. 71, No. 6, 1570-1576.



Example 1

■ Maternal Vitamin Supplementation and Infant Mortality



■ Log rank test


■ Interpretation?

Examples 2

 Return to Work Following Injury: The Role of Economic, Social, and Job-Related Factors²

"The main dependent variable in the analysis is the time (in days) from injury to the first time the study patient returned to work. Kaplan-Meier estimates of the cumulative proportion of patients returning to work were computed. These estimates take into account how long patients were followed as well as when they returned to work. A log-rank test was used to test the association between the cumulative probability of RTW and each of the risk factors considered one at a time"

 2 MacKenzie E, et al Return to Work Following Injury:The Role of Economic, Social, and Job-Related Factors $\it America Journal of Public Health 88; 11 (1998)$



■ Post partum ART therapy for children born to HIV positive women³

- BACKGROUND

 It saftly and efficacy of adding satiseteorial drugs to standard aidowedine prophylaxia in infasts of mothers with human immunodeficiency virus (HIV) infection
 all who did not receive astenatial satiseteorial thempy (ART) because of late identify
 action are non-lear. We evaluate three ART regimens in such infasts.

- section are unclear. We evaluated three ART regimens in such infinits.

 MINDOS


 Whin 48 hours after their birth, we randomly assigned formula-fed infinits born to women with a perjustrum diagnosis of HIV type 1 (HIV-1) infection to one of three regimens: addovaline for 6 weeks (zidovadine-slone group), zidovadine for 6 weeks in pixs three doses of neirispine dozing the first 8 days of life (two-drug group), or zidovadine for 6 weeks pixs inclinitive and nimivadine for 2 weeks three-drug group).

 The primary outcome was HIV-1 infection at 3 months in infinits uninfected at birth.

3 Nielson-Saines K, et al. Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV Infection. New England Journal of Medicine (2012). 366 (25).

Example 3

• Post partum ART therapy for children born to HIV positive women



"Kaplan–Meier curves for intrapartum transmission differed significantly (P = 0.03 for the overall comparison).

Transmission rates were highest in the zidovudine-alone group (3.4% at 4 to 6 weeks vs. 1.6% in the two-drug group and 1.4% in the three-drug group; 4.8% at 3 months vs. 2.2% in the two-drug group and 2.4% in the three-drug group)."

Example 3

Post partum ART therapy for children born to HIV positive women

CONCLUSIONS

In neonates whose mothers did not receive ART during pregnancy, prophylaxis with a
tow- or three-deng ART regimen is superior to aidovodine alone for the prevention of
intrapartum HIV transmission, the two-drug regimen has less toxicity than the threedrug regimen. (Bonded by the Bonice Kennedyshirer withsoul Institute of Child Health
and Homan Development (BGCHD) and others, Clinical Trials gow number, NCT00099959)

Summary